Etisomicin is a semisynthetic aminoglycoside antibiotic.

Pumosetrag is a novel, orally active and selective 5-HT 3 agonist. It is a partial agonist in rats and guinea-pig and a full agonist in the mouse, suggesting important species differences in 5-HT3 receptor structure. Pumosetrag had been in phase II clinical trials for the treatment of gastroesophageal reflux disease and irritable bowel syndrome. No serious adverse events were reported. Diarrhea was not more common on the drug and only one subject experienced pruritus. All researches on this drug candidate are discontinued.

Nelezaprine is a skeletal muscle relaxant.

Canbisol is dihydroxyhexahydrodibenzo(b,d)pyran derivative patented by pharmaceutical company Eli Lilly and Co. as antihypertensive agent. At the dosages studied, Canbisol reduced food consumption by rats.

Dexpemedolac is long-acting non-narcotic analgesic. Dexpemedolac exhibited potent analgesic effects against chemically induced pain in rats and mice and against inflammatory pain in rats. Dexpemedolac differed from standard nonsteroidal anti-inflammatory drugs (NSAIDs) in that the doses, which produced analgesia were much lower than those required for either anti-inflammatory or gastric irritant effects. The common to the NCAIDs class actions are antipyresis and inhibitory effects on platelet aggregation. In yeast-induced hyperthermic rats, dexpemedolac exhibited antipyretic actions, whereas the drug did not affect body temperature in normothermic animals. Aggregation of human platelets was inhibited by high concentrations of dexpemedolac.

There is no much information related to the pharmacological and/or biological properties of parapropamol. However, the analgesic properties of this compound had been studied in dentistry.

Quilostigmine (also known as NXX-066) is an isoquinolinecarboxylate patented by Hoechst-Roussel Pharmaceuticals Inc as a memory enhancer. Quilostigmine acts as acetylcholinesterase inhibitor and studies as a potential drug for treating Alzheimer’s disease. Quilostigmine is well absorbed from the gastrointestinal tract, but the oral bioavailability poor to moderate in rats and dogs because of pre-systemic metabolism. In preclinical studies has demonstrated activity in animal models of memory function. In clinical trials, Quilostigmine was well tolerated in healthy subjects up to a single dose of 64 mg and multiple doses of 60 mg QD for seven days

Metoxepin was developed as an antiemetic, neuroleptic and antihistamine agent. This drug has never been marketed.

Mezepine is an antidepressive agent, that has never been marketed.